期刊文献+

福安泰-03对人脐静脉内皮细胞凋亡和小鼠创伤愈合的影响

Effects of Fuantai-03 Isolated from Dasyatis akajei on the Apoptosis of Human Umbilical Vein Endothelial Cells and Mouse Wound Healing
原文传递
导出
摘要 研究福安泰-03(Fuantai,FAT-03)对人脐静脉血管内皮细胞(human umbilical vein en-dothelial cells,HUVECs)凋亡和小鼠创伤愈合的影响。MTT法检查FAT-03对HUVECs和人低分化鼻咽癌细胞(CNE-2Z)生长的影响;聚碳酸酯膜小室趋化运动模型(Transwell model)检测FAT-03对HU-VECs运动能力的影响;荧光显微镜观察FAT-03作用下HUVECs的形态变化;膜联蛋白V-异硫氰酸荧光素(Annexin V-fluorescein isothiocyanate,Annexin V-FITC)双染检测FAT-03对HUVECs早期凋亡的影响;流式细胞术分析FAT-03对HUVECs周期及凋亡的影响;Western blot法分析FAT-03对HUVECs的血管内皮细胞生长因子(VEGF)、Bcl-2、Bax表达的影响;小鼠背部创伤模型检查FAT-03对组织修复的影响;免疫组化法检查FAT-03对创伤组织微血管密度(microvessel density,MVD)和VEGF表达的影响。结果显示,FAT-03明显抑制HUVECs细胞的增殖和迁移,其抑制效果与剂量和作用时间相关,作用HUVECs 24,48,72 h的IC50值为0.22,0.17,0.09 mg/mL,但FAT-03对CNE-2Z细胞的生长却无明显的影响;0.16 mg/mL FAT-03作用HUVECs 24 h对细胞迁移的抑制率为57.9%(P<0.01);FAT-03处理HUVECs 48 h,细胞的早期凋亡率增加(P<0.05);FAT-03阻滞HUVECs于G0/G1期,并呈现典型的凋亡峰;0.16 mg/mL FAT-03作用48,72 h,HUVECs的凋亡率分别为14.6%、41.7%;FAT-03下调HUVECs的VEGF和抑凋亡基因Bcl-2的表达,上调促凋亡基因Bax的表达,其效果与剂量相关。FAT-03明显延迟小鼠创伤的愈合,且其作用与剂量相关。FAT-03组小鼠创伤周围组织微血管密度和VEGF阳性表达细胞都明显减少。因此,可以推测,FAT-03抑制HUVECs增殖并诱导其凋亡;抑制创伤组织的血管生成,进而延迟创伤愈合;它的这些作用可能与其下调VEGF、Bcl-2的表达,上调Bax的表达相关。 The present study was undertaken to investigate the effects of Fuantai-03 (FAT-03) isolated from Dasyat akajei effected on the apoptosis of human umbilical vein endothelial cells and wound healing. MTT assay was performed to measure the effect of FAT-03 on cell growth; migration assay was performed using a Tran- swell model with polycarbonate membrane; apoptotic induction was determined by fluorescence microscopy and flow cytometry; Western blot analysis was performed for examing expressions of vascular endothelial growth factor (VEGF), Bcl-2 and Bax. Mouse wound model was applied to investigate the effect of FAT-03 on wound healing; immunohistochemical staining assay was adopted to examine the microvessel density (MVD) and expression of VEGF in wound tissues. FAT-03 obviously inhibited proliferation and migration of HUVECs in a dose- and time- dependent manner the values of IC50 for the effect of FAT-03 on HUVECs at 24, 48, 72 h are 0.22 mg/mL, 0.17 mg/mL, 0.09 mg/mL, respectively, but FAT-03 did not show significant effect on the growth of human nasopharyngeal car- cinoma cell line (CNE-2Z). 0.16 mg/mL FAT-03 decreased the percentage of migrating HUVECs at 24 h by 57.9% (P〈0.01). FAT-03-treated HUVECs showed typical morphologic and cellular evidences of apoptosis. The expres- sions of VEGF and Bcl-2 in the FAT-03-treated HUVECs were evidently down-regulated, and the expression of Bax was obviously up-regulated. FAT-03 markedly decreased the MVD (P〈0.05) and down-regulated the expression of VEGF in mouse wound tissues, and inhibited tissue repairing. These findings provide evidences that FAT-03 signifi- cantly inhibits the proliferation and migration of HUVECs and induces their apoptosis, and inhibits tissue repairing in mouse wound model. The effects of FAT-03 might result from the down-regulation of expressions of VEGF and Bcl-2 and up-regulation of expression of Bax.
出处 《中国细胞生物学学报》 CAS CSCD 北大核心 2012年第4期332-342,共11页 Chinese Journal of Cell Biology
基金 "863"海洋技术领域专题(No.2007AA092422) 国家自然科学基金(No.30271493) 广东省自然科学基金重点项目(No.021386) 广东省海洋与渔业局科技兴海重大项目(No.A200099B01)资助项目~~
关键词 福安泰-03 人脐静脉内皮细胞 细胞凋亡 血管内皮细胞生长因子 凋亡相关基因 微血管密度 创伤愈合 小鼠 Fuantai-03 human umbilical vein endothelial cells apoptosis vascular endothelial growthfactor apoptosis-related genes microvessel density wound healing mice
  • 相关文献

参考文献8

二级参考文献95

  • 1翟福林,庄英帜,曹建国.罗格列酮下调肺腺癌细胞血管内皮细胞生长因子的表达[J].中国药理学通报,2006,22(10):1254-1258. 被引量:4
  • 2Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors [J]. Breast Cancer Res Treat,1995,36(2) :169 -80.
  • 3Zheng L, Wang Z, Niu R, et al. A novel peptide from shark cartilage with potent antiangiogenesis activity [ J ]. Cancer Biol Ther, 2007,6 ( 5 ) :775 - 80.
  • 4Gingras D, Boivin D, Deckers C, et al. Neovastat-a novel antiangiogenic drug for cancer therapy [ J ]. Anticancer Drugs,2003,14 ( 2 ) : 91 -6.
  • 5Falardeau P, Champagne P, Poyet P, et al. A naturally ocurring multifunctional antiangiogenic drug, in phase Ⅲ clinical trials [ J ]. Semin Oncol,2001,28 ( 6 ) :620 - 5.
  • 6Gingras D, Labelle D, Nyalendo C, et al. The antiangiogenic agent Neovastat ( AE-941 ) stimulates tissue plasminogen activator activity [ J ]. Invest New Drug, 2004,22 ( 1 ) : 17 - 26.
  • 7Carmeliet P. Angiogenesis in life, disease and medicine [ J ]. Nature,2005,438(12) :932 -6.
  • 8Folkman J. Tumor angiogenesis : therapeutic implications [ J ]. N Engl J Med, 1971,285 (21) : 1182 - 6.
  • 9Pandya N M, Dhalla N S, Santani D D. Angiogenesis-a new target for future therapy [ J ]. Vasc Pharmacol, 2006,44 ( 5 ) : 265 - 74.
  • 10Folkman J. New perspectives in clinical ontology from angiogenesis research[J]. Eur J Cancer ,1996 ,32A (14 ) :2534 -9.

共引文献173

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部